Last Updated on January 3, 2024 by The Health Master
Marksans Pharma yesterday said its subsidiary has received market authorisation from the UK health regulator for its anti-diarrhoea medication, Loperamide capsules.
The UK MHRA has granted market authorisation to the company’s wholly-owned subsidiary Relonchem for Loperamide hard capsules (2 mg), Marksans Pharma said in a regulatory filing.
It also said that it would manufacture the product at its Goa-based oral dosage facility.
UK MHRA: The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK. MHRA is an executive agency, sponsored by the Department of Health and Social Care.
High Court quashed the criminal complaint of alleged NSQ drug
Medical treatments may get more expensive for you from next year
Increase in Pharmacy colleges to meet rising demand of Medical Stores
Pharmexcil is seeking candidates for the role of Director
IPC flags safety alert against NSAID Diclofenac
Narcotics Drugs: Team raids Zirakpur Pharmaceuticals firm
Sun Pharma gets CDSCO panel nod for FDC Brinzolamide, Timolol, Pot…
Procedure for registration of Medical Devices: CDSCO
Latest Notifications regarding Pharmaceuticals
